Activity of comets: Insights from ground-based broadband observations

Comets are the primitive building blocks of the Solar System. In order to understand the extent of the pristine nature of comets, we must understand the mechanisms that affect their surfaces and comae -- their activity. Activity can be tracked in a variety of ways, such as observing dust production in the coma using broadband imaging. Activity varies from comet to comet so we must try to distinguish whether these differences in activity are because of ageing or reflect primordial differences. Ageing refers to effects that have chemically or physically altered the nucleus since its formation and cause a change in the activity. I developed a pipeline to calibrate and measure broadband photometry of comets in a consistent way. The pipeline calibrates the brightness to a common photometric system using background stars in the field. I applied this pipeline to ground-based data accompanying the Rosetta mission. The photometry of 67P followed the predictions based on previous apparitions: it showed no obvious change in activity levels from orbit-to-orbit and coma colours remained constant throughout the apparition. I detected an outburst on 2015 August 22 of ∼0.14 mag. The brightness and estimated mass of this outburst put it in line with the outbursts directly observed on the nucleus by Rosetta. An in situ outburst was observed at the same time as the one seen from the ground; however, linking these two events directly remains challenging. I applied the pipeline to TRAPPIST photometry of 14 comets. I determined that comets of different dynamical classes can be distinguished by their dust activity: dynamically new comets displayed higher dust production rates and greater asymmetries in the dust production rates about perihelion than other comets. There seemed to be no correlation as to whether the peak of activity occurred before or after perihelion. I found strong relationships between dust and gas production which can be used as a rough approximation of gas production rates if one is only presented with broadband data. I found that a decrease in V− R colour is strongly correlated with an increase in gas production pre-perihelion

Searching for Outbursts in the Ground-Based Photometry of 67P/Churyumov-Gerasimenko

67P/Churyumov-Gerasimenko is a Jupiter-family comet that was the target of the Rosetta mission, the first mission to successfully orbit and land a probe on a comet. This mission was accompanied by a large ground-based observing campaign. We have developed a pipeline to calibrate and measure photometry of comet 67P during its 2016 perihelion passage, making use of all visible wavelength broadband imaging collected across a wide range of facilities. The pipeline calibrates the brightness of the comet to a common photometric system (Pan-STARRS 1) using background stars within the field allowing for compilation and comparison of multiple data sets. Results follow the predictions based on previous apparitions: 67P shows no obvious change in activity levels from orbit-to-orbit and coma colours remain constant throughout the apparition. We detected an outburst on 2015 August 22 of ∼0.14 mag. The brightness and estimated mass of this outburst puts it in line with the outbursts directly observed on the nucleus by Rosetta. An in situ outburst was observed at the same time as the one seen from the ground, however linking these two events directly remains challenging

Investigating the field-dependence of the Davis model: Calibrated fMRI at 1.5, 3 and 7 T

Gas calibrated fMRI in its most common form uses hypercapnia in conjunction with the Davis model to quantify relative changes in the cerebral rate of oxygen consumption (CMRO2) in response to a functional stimulus. It is most commonly carried out at 3 T but, as 7 T research scanners are becoming more widespread and the majority of clinical scanners are still 1.5 T systems, it is important to investigate whether the model used remains accurate across this range of field strengths. Ten subjects were scanned at 1.5, 3 and 7 T whilst performing a bilateral finger-tapping task as part of a calibrated fMRI protocol, and the results were compared to a detailed signal model. Simulations predicted an increase in value and variation in the calibration parameter M with field strength. Two methods of defining experimental regions of interest (ROIs) were investigated, based on (a) BOLD signal and (b) BOLD responses within grey matter only. M values from the latter ROI were in closer agreement with theoretical predictions; however, reassuringly, ROI choice had less impact on CMRO2 than on M estimates. Relative changes in CMRO2 during motor tasks at 3 and 7 T were in good agreement but were over-estimated at 1.5 T as a result of the lower signal to noise ratio. This result is encouraging for future studies at 7 T, but also highlights the impact of imaging and analysis choices (such as ASL sequence and ROI definition) on the calibration parameter M and on the calculation of CMRO2

VLT/MUSE Characterization of Dimorphos Ejecta from the DART Impact

We have observed the Didymos-Dimorphos binary system with the MUSE integral field unit spectrograph mounted at the Very Large Telescope before and after DART impact and captured the ensuing ejecta cone, debris cloud, and tails at subarcsecond resolutions. We targeted the Didymos system over 11 nights from 2022 September 26 to October 25 and utilized both narrow- and wide-field observations with and without adaptive optics, respectively. We took advantage of the spectral–spatial coupled measurements and produced both white-light images and spectral maps of the dust reflectance. We identified and characterized numerous dust features, such as the ejecta cone, spirals, wings, clumps, and tails. We found that the base of the sunward edge of the wings, from October 3 to 19, is consistent with maximum grain sizes on the order of 0.05–0.2 mm and that the earliest detected clumps have the highest velocities, on the order of ;10 m s−1. We also see that three clumps in narrow-field mode (8″ × 8″) exhibit redder colors and slower speeds, around 0.09 m s−1, than the surrounding ejecta, likely indicating that the clump is composed of larger, slower grains. We measured the properties of the primary tail and resolved and measured the properties of the secondary tail earlier than any other published study, with first retrieval on October 3. Both tails exhibit similarities in curvature and relative flux; however, the secondary tail appears thinner, which may be caused by lower-energy ejecta and possibly a low-energy formation mechanism such as secondary impacts

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid (n = 187) and serum (n = 405) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer's disease. Longitudinal, within-person analysis of serum NfL dynamics (n = 196) confirmed this elevation and further revealed that the rate of change of serum NfL could discriminate mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked in participants converting from the presymptomatic to the symptomatic stage and was associated with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-β deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was predictive for both the rate of cortical thinning and cognitive changes assessed by the Mini-Mental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer's disease, which supports its potential utility as a clinically useful biomarker

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Optical Monitoring of the Didymos–Dimorphos Asteroid System with the Danish Telescope around the DART Mission Impact

The NASA’s Double-Asteroid Redirection Test (DART) was a unique planetary defence and technology test mission, the first of its kind. The main spacecraft of the DART mission impacted the target asteroid Dimorphos, a small moon orbiting the asteroid Didymos (65803), on 2022 September 26. The impact brought up a mass of ejecta which, together with the direct momentum transfer from the collision, caused an orbital period change of 33 ± 1 minutes, as measured by ground-based observations. We report here the outcome of the optical monitoring campaign of the Didymos system from the Danish 1.54 m telescope at La Silla around the time of impact. The observations contributed to the determination of the changes in the orbital parameters of the Didymos–Dimorphos system, as reported by Thomas et al., but in this paper we focus on the ejecta produced by the DART impact. We present photometric measurements from which we remove the contribution from the Didymos–Dimorphos system using an H–G photometric model. Using two photometric apertures we determine the fading rate of the ejecta to be 0.115 ± 0.003 mag day−1 (in a 2″ aperture) and 0.086 ± 0.003 mag day−1 (5″) over the first week postimpact. After about 8 days postimpact we note the fading slows down to 0.057 ± 0.003 mag day−1 (2″ aperture) and 0.068 ± 0.002 mag day−1 (5″). We include deep-stacked images of the system to illustrate the ejecta evolution during the first 18 days, noting the emergence of dust tails formed from ejecta pushed in the antisolar direction, and measuring the extent of the particles ejected Sunward to be at least 4000 km

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention